THE EFFECT OF INOSITOL ON WOMEN WITH POLYCYSTIC OVARY SYNDROME AND OBESITY: METABOLIC AND REPRODUCTIVE ASPECTS
(LITERATURE REVIEW)
DOI:
https://doi.org/10.11603/24116-4944.2024.1.14741Keywords:
infertility, obesity, polycystic ovary syndrome, insulin resistance, anovulation, inositolAbstract
The aim of the study - to assess the impact of obesity and determine the effectiveness of pregravid preparation in patients with polycystic ovary syndrome (PCOS) in assisted reproductive technology (ART) protocols.
Materials and Methods. A systematic review and comparative analysis of 44 scientific publications and literature sources from the PubMed database over the past 5 years related to research in the field of reproductive medicine on the impact of polycystic ovary syndrome and obesity on the reproductive potential of women and methods of pathogenetic correction at the stage of pregravid preparation was conducted.
Results and Discussion. The analysis of literature data showed that inositol helps to improve the metabolic profile, reduce insulin resistance and regulate hormonal balance. In addition, inositol intake improves reproductive functions and helps to improve the quality of eggs in in vitro fertilization protocols. The results confirm the feasibility of using inositol as part of a comprehensive approach to the treatment of women with PCOS and obesity, opening up prospects for further research in this area.
Conclusions. Polycystic ovary syndrome is a complex heterogeneous disease that requires an integrated approach to management. The use of inositol in women with comorbid PCOS and obesity demonstrates positive effects in the context of the metabolic profile and reproductive health of this group of women.
References
1. Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022). Polycystic ovary syndrome. The Lancet. Diabetes & Endocrinology, 10(9), 668–680. DOI: https://doi.org/10.1016/S2213-8587(22)00163-2
2. Aversa, A., La Vignera, S., Rago, R., Gambineri, A., Nappi, R. E., Calogero, A. E., & Ferlin, A. (2020). Fundamental concepts and novel aspects of polycystic ovarian syndrome: expert consensus resolutions. Frontiers in Endocrinology, 11, 516. DOI: https://doi.org/10.3389/fendo.2020.00516.
3. Christ, J. P., & Cedars, M. I. (2023). Current guidelines for diagnosing PCOS. Diagnostics (Basel, Switzerland), 13(6), 1113. DOI: https://doi.org/10.3390/diagnostics13061113
4. Carmina, E., Azziz, R., Bergfeld, W., Escobar-Morreale, H. F., Futterweit, W., Huddleston, H., Lobo, R., & Olsen, E. (2019). Female pattern hair loss and androgen excess: a report from the Multidisciplinary Androgen Excess and PCOS Committee. The Journal of Clinical Endocrinology and Metabolism, 104(7), 2875–2891. DOI: https://doi.org/10.1210/jc.2018-02548
5. Polycystic ovary/ovarian syndrome (PCOS). (2019). NIH. Retrieved from https://orwh.od.nih.gov/sites/orwh/files/docs/PCOS_Booklet_508.pdf
6. Deswal, R., Narwal, V., Dang, A., & Pundir, C. S. (2020). The prevalence of polycystic ovary syndrome: a brief systematic review. Journal of Human Reproductive Sciences, 13(4), 261–271. DOI: https://doi.org/10.4103/jhrs.JHRS_95_18
7. Johnson, J. E., Daley, D., Tarta, C., & Stanciu, P. I. (2023). Risk of endometrial cancer in patients with polycystic ovarian syndrome: A meta-analysis. Oncology Letters, 25(4), 168. DOI: https://doi.org/10.3892/ol.2023.13754
8. Patten, R. K., Pascoe, M. C., Moreno-Asso, A., Boyle, R. A., Stepto, N. K., & Parker, A. G. (2021). Effectiveness of exercise interventions on mental health and health-related quality of life in women with polycystic ovary syndrome: a systematic review. BMC Public Health, 21(1), 2310. DOI: https://doi.org/10.1186/s12889-021-12280-9
9. Khmil Doswald, A. S., Khmil, M. S., & Khmil, S. V. (2021). Epidemiology of polycystic ovary syndrome, endometriosis and their comorbid course. Bulletin of Medical and Biological Research, 3(4), 135–145. DOI: https://doi.org/10.11603/bmbr.2706-6290.2021.4.12662
10. Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022). Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. International Journal of Molecular Sciences, 23(8), 4110. DOI: https://doi.org/10.3390/ijms23084110
11. Stener-Victorin, E., Teede, H., & Piltonen, T. T. (2024). Polycystic ovary syndrome. Nature Reviews Disease Primers, 10, 28. DOI: https://doi.org/10.1038/s41572-024-00517-x
12. Ajmal, N., Khan, S. Z., & Shaikh, R. (2019). Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. European Journal of Obstetrics & Gynecology and Reproductive Biology: X, 3, 100060. DOI: https://doi.org/10.1016/j.eurox.2019.100060
13. Velazquez, M. E., Millan, A. L., Rojo, M., Abruzzese, G. A., Cocucci, S. E., Iglesias Molli, A. E., Frechtel, G. D., Motta, A. B., & Cerrone, G. E. (2021). Telomere length differently associated to obesity and hyperandrogenism in women with polycystic ovary syndrome. Frontiers in Endocrinology, 12, 604215. DOI: https://doi.org/10.3389/fendo.2021.604215
14. Yang, Z., Shi, J., Guo, Z., Chen, M., Wang, C., He, C., & Zuo, Z. (2019). A pilot study on polycystic ovarian syndrome caused by neonatal exposure to tributyltin and bisphenol A in rats. Chemosphere, 231, 151–160. DOI: https://doi.org/10.1016/j.chemosphere.2019.05.129
15. Khmil, M., Khmil, S., & Marushchak, M. (2020). Hormone imbalance in women with infertility caused by polycystic ovary syndrome: is there a connection with body mass index? Open Access Macedonian Journal of Medical Sciences, 8(B), 731–737. https://doi.org/10.3889/oamjms.2020.4569
16. Khmil, M. S., Khmil Doswald, A. S., & Khmil, S. V. (2019). Polycystic ovary syndrome as a factor in endocrine infertility. Bulletin of Medical and Biological Research, (2), 77–83.
17. Munro, M. G., Balen, A. H., Cho, S., Critchley, H. O., Díaz, I., Ferriani, R., ... & van der Spuy, Z. M. (2022). The FIGO ovulatory disorders classification system. Human Reproduction, 37(10), 2446–2464. DOI: https://doi.org/10.1093/humrep/deac180
18. Daghestani, M. H., Daghestani, M. H., Warsy, A., El-Ansary, A., Omair, M. A., Omair, M. A., Hassen, L. M., Alhumaidhi, E. M., Al Qahtani, B., & Harrath, A. H. (2021). Adverse effects of selected markers on the metabolic and endocrine profiles of obese women with and without PCOS. Frontiers in Endocrinology, 12, 665446. DOI: https://doi.org/10.3389/fendo.2021.665446
19. Astapova, O., Minor, B. M. N., & Hammes, S. R. (2019). Physiological and pathological androgen actions in the ovary. Endocrinology, 160(5), 1166–1174. DOI: https://doi.org/10.1210/en.2019-00101
20. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & International PCOS Network. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602–1618. DOI: https://doi.org/10.1093/humrep/dey256
21. Li, Y., Wang, Y., Liu, H., Zhang, S., & Zhang, C. (2023). Association between HOMA-IR and ovarian sensitivity index in women with PCOS undergoing ART: A retrospective cohort study. Frontiers in Endocrinology, 14, 1117996. DOI: https://doi.org/10.3389/fendo.2023.1117996
22. Zheng, Y., Pan, Y., Li, P., Wang, Z., Wang, Z., & Shi, Y. (2022). Ovarian sensitivity decreased significantly in patients with insulin resistance undergoing in vitro fertilization and embryo transfer. Frontiers in Physiology, 12, 809419. DOI: https://doi.org/10.3389/fphys.2021.809419
23. De Diego, M. V., Gómez-Pardo, O., Groar, J. K., López-Escobar, A., Martín-Estal, I., Castilla-Cortázar, I., & Rodríguez-Zambrano, M. Á. (2020). Metabolic impact of current therapeutic strategies in polycystic ovary syndrome: a preliminary study. Archives of Gynecology and Obstetrics, 302(5), 1169–1179. DOI: https://doi.org/10.1007/s00404-020-05696-y
24. Le Donne, M., Metro, D., Alibrandi, A., Papa, M., & Benvenga, S. (2019). Effects of three treatment modalities (diet, myo-inositol or myo-inositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences, 23(5), 2293–2301. DOI: https://doi.org/10.26355/eurrev_201903_17278
25. Roseff, S., & Montenegro, M. (2020). Inositol treatment for PCOS should be science-based and not arbitrary. International Journal of Endocrinology, 2020, 6461254. DOI: https://doi.org/10.1155/2020/6461254
26. Herman, R., Sikonja, J., Jensterle, M., Janez, A., & Dolzan, V. (2023). Insulin metabolism in polycystic ovary syndrome: secretion, signaling, and clearance. International Journal of Molecular Sciences, 24(4), 3140. DOI: https://doi.org/10.3390/ijms24043140
27. Unluhizarci, K., Karaca, Z., & Kelestimur, F. (2021). Role of insulin and insulin resistance in androgen excess disorders. World Journal of Diabetes, 12(5), 616–629. DOI: https://doi.org/10.4239/wjd.v12.i5.616
28. Wojciechowska, A., Osowski, A., Jóźwik, M., Górecki, R., Rynkiewicz, A., & Wojtkiewicz, J. (2019). Inositols' importance in the improvement of the endocrine-metabolic profile in PCOS. International Journal of Molecular Sciences, 20(22), 5787. DOI: https://doi.org/10.3390/ijms20225787
29. Januszewski, M., Issat, T., Jakimiuk, A. A., Santor-Zaczynska, M., & Jakimiuk, A. J. (2019). Metabolic and hormonal effects of a combined myo-inositol and D-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekologia Polska, 90(1), 7–10. https://doi.org/10.5603/GP.2019.0002
30. Kamenov, Z., & Gateva, A. (2020). Inositols in PCOS. Molecules (Basel, Switzerland), 25(23), 5566. DOI: https://doi.org/10.3390/molecules25235566
31. Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C. (2024). Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. The Journal of Clinical Endocrinology and Metabolism, 109(6), 1630–1655. DOI: https://doi.org/10.1210/clinem/dgad762
32. Pkhaladze, L., Unfer, V., & Dewailly, D. (2023). Use of myo-inositol in the treatment of PCOS symptoms in adolescents. In A Clinical Guide to Inositols (pp. 151–165). Academic Press. https://doi.org/10.1016/B978-0-323-91673-8.00001-7
33. Bevilacqua, A., Dragotto, J., Giuliani, A., & Bizzarri, M. (2019). Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. Journal of Cellular Physiology, 234(6), 9387–9398. DOI: https://doi.org/10.1002/jcp.27623
34. Nordio, M., Basciani, S., & Camajani, E. (2019). The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences, 23(12), 5512–5521. DOI: https://doi.org/10.26355/eurrev_201906_18223
35. Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019). Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecological Endocrinology, 35(8), 695–700. DOI: https://doi.org/10.1080/09513590.2019.1576620
36. Khmil, S. V., Denefil, O. V., Terletska, N. Y., Khmil, M. S., & Petryshyn, N. Y. (2023). Influence of inositol on the body and reproductive function of a woman. Achievements of Clinical and Experimental Medicine, (4), 35–41. DOI: 10.11603/1811-2471.2022.v.i4.13495
37. Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., Soulage, C. O., & Group of "Inositol in PCOS and Reproduction". (2020). Inositols in polycystic ovary syndrome: an overview on the advances. Trends in Endocrinology and Metabolism, 31(6), 435–447. DOI: https://doi.org/10.1016/j.tem.2020.02.002
38. Merviel, P., James, P., Bouée, S., Le Guillou, M., Rince, C., Nachtergaele, C., & Kerlan, V. (2021). Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reproductive Health, 18(1), 13. DOI: https://doi.org/10.1186/s12978-021-01073-3
39. Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020). Altered ovarian inositol ratios may account for pathological steroidogenesis in PCOS. International Journal of Molecular Sciences, 21(19), 7157. DOI: https://doi.org/10.3390/ijms21197157
40. Dason, E. S., Koshkina, O., Chan, C., & Sobel, M. (2024). Diagnosis and management of polycystic ovarian syndrome. CMAJ, 196(3), E85–E94. DOI: https://doi.org/10.1503/cmaj.231251
41. Akbari Sene, A., Tabatabaie, A., Nikniaz, H., Alizadeh, A., Sheibani, K., Mortezapour Alisaraie, M., Tabatabaie, M., Ashrafi, M., & Amjadi, F. (2019). The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Archives of Gynecology and Obstetrics, 299(6), 1701–1707. DOI: https://doi.org/10.1007/s00404-019-05111-1
42. Troisi, J., Cinque, C., Giugliano, L., Symes, S., Richards, S., Adair, D., Cavallo, P., Sarno, L., Scala, G., Caiazza, M., & Guida, M. (2019). Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. Journal of Ovarian Research, 12(1), 25. DOI: https://doi.org/10.1186/s13048-019-0500-x
43. Terletska, N. Yu., Denefil, O. V., Khmil, S. V., & Kramar, S. B. (2023). The role of inflammation in ovarian pathology as a predictor of the development of sterility and its correction by inositol medications. Bukovynskyi Medychnyi Visnyk, 27(3(107)), 57–64. DOI: https://doi.org/10.24061/2413-0737.27.3.107.2023.10 [In Ukrainian]
44. Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R. (2022). Efficacy of myo-inositol on anthropometric, metabolic, and endocrine outcomes in PCOS patients: a meta-analysis of randomized controlled trial. Reproductive Sciences, 29(8), 2282–2298. DOI: https://doi.org/10.1007/s43032-022-00933-y
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Actual Problems of Pediatrics, Obstetrics and Gynecology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
